GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dae Hwa Pharm Co Ltd (XKRX:067080) » Definitions » EV-to-EBITDA

Dae Hwa Pharm Co (XKRX:067080) EV-to-EBITDA : 15.06 (As of May. 27, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dae Hwa Pharm Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dae Hwa Pharm Co's enterprise value is ₩269,430 Mil. Dae Hwa Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩17,891 Mil. Therefore, Dae Hwa Pharm Co's EV-to-EBITDA for today is 15.06.

The historical rank and industry rank for Dae Hwa Pharm Co's EV-to-EBITDA or its related term are showing as below:

XKRX:067080' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.75   Med: 22.83   Max: 89.1
Current: 15.05

During the past 13 years, the highest EV-to-EBITDA of Dae Hwa Pharm Co was 89.10. The lowest was 6.75. And the median was 22.83.

XKRX:067080's EV-to-EBITDA is ranked worse than
52.59% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.57 vs XKRX:067080: 15.05

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Dae Hwa Pharm Co's stock price is ₩9840.00. Dae Hwa Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-237.453. Therefore, Dae Hwa Pharm Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Dae Hwa Pharm Co EV-to-EBITDA Historical Data

The historical data trend for Dae Hwa Pharm Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dae Hwa Pharm Co EV-to-EBITDA Chart

Dae Hwa Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.03 31.65 20.14 26.84 26.32

Dae Hwa Pharm Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.86 22.27 47.32 26.32 10.30

Competitive Comparison of Dae Hwa Pharm Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Dae Hwa Pharm Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dae Hwa Pharm Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dae Hwa Pharm Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dae Hwa Pharm Co's EV-to-EBITDA falls into.



Dae Hwa Pharm Co EV-to-EBITDA Calculation

Dae Hwa Pharm Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=269430.404/17891.303
=15.06

Dae Hwa Pharm Co's current Enterprise Value is ₩269,430 Mil.
Dae Hwa Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩17,891 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dae Hwa Pharm Co  (XKRX:067080) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Dae Hwa Pharm Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9840.00/-237.453
=At Loss

Dae Hwa Pharm Co's share price for today is ₩9840.00.
Dae Hwa Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-237.453.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Dae Hwa Pharm Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dae Hwa Pharm Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dae Hwa Pharm Co (XKRX:067080) Business Description

Traded in Other Exchanges
N/A
Address
495 Hanu-ro, Hoengseong-eup, Hoengseong-gun, Seoul, Gangwon-do, KOR, 225-804
Dae Hwa Pharm Co Ltd is a specialized pharmaceutical company. It is mainly involved in manufacturing and distribution of pharmaceutical products. The company controls approximately 70% of the domestic transdermal drug delivery system market. The company offers analgesics and anti-inflammatory drugs, antihistamines, skeletal muscle relaxants, and cardiovascular drugs. Its products are exported to Asia, South America, Africa, and the Middle East.

Dae Hwa Pharm Co (XKRX:067080) Headlines

No Headlines